GWPH News and Press, GW Pharmaceuticals Plc From 12/11/19

In the past year or so marijuana stocks have faced more hurdles. Many of these obstacles are legislative issues. However, in the midst of all this, public perception has also changed. Currently, in the cannabis industry , we are seeing a high level of volatility sweeping through the market. I...

The Food and Drug Administration still refuses to acknowledge electronic cigarettes may be a healthier alternative to traditional cigarettes, even though much of the rest of the world actively promotes smokers switching to e-cigs as safer. The agency used an outbreak of lung injuries and deaths...

Aurora Cannabis (NYSE: ACB) and GW Pharmaceuticals (NASDAQ: GWPH) are two cannabis companies seemingly going in different directions. It's not just their strategies that are different; so are their financials and their stock performances. Year to date, Aurora has lost more than half of i...

CARLSBAD, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today presented new data from a Phase 3 cli...

GW Pharmaceuticals plc (GWPH) Credit Suisse 7th Annual Industrials Conference December 5, 2019 8:30 AM ET Company Participants Justin Gover – Chief Executive Officer Conference Call Participants Danielle Brill – Piper Jaffray Presentation Danielle Brill ...

As recently as the end of March, cannabis stocks were chugging along and handily outpacing the returns of the broader market. At one point, there were more than one dozen marijuana stocks sporting a market cap of at least $1 billion. But times have definitely changed. Since the first quarter ...

LONDON and CARLSBAD, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences announced today that a variety of...

Marijuana stock investors are probably thankful that there are only a few weeks left in 2019. It's been a stinker of a year for them, with pot investments diving in value due to a myriad of negative factors (supply issues in Canada, high taxation on cannabis in key U.S. states that have lega...

When the year began, the North American cannabis industry looked to have plenty of momentum. Canada had just become the first industrialized country in the modern era to green-light adult-use cannabis, Mexico looked to be on track to legalize recreational pot later in the year, and support for...

The share prices of several notable marijuana stocks are slumping on a new warning about cannabidiol (CBD) from the U.S. Food and Drug Administration (FDA). Yesterday the health industry regulator issued a new "consumer update" regarding CBD, the nonpsychoactive ingredient in cannabis that pr...